Company Overview
Nyxoah SA functions as a medical technology enterprise dedicated to the development and commercialization of therapeutic solutions specifically designed to address obstructive sleep apnea (OSA). Operating within the healthcare sector and the specialized industry of medical instruments and supplies, the company focuses on delivering patient-centric, minimally invasive interventions. The company's primary product offering is the Genio system, which utilizes hypoglossal neurostimulation therapy to treat moderate to severe forms of obstructive sleep apnea. Currently, Nyxoah SA holds a market capitalization of $138.41M and reports trailing twelve-month revenue of $10.02M, while the employee count is not publicly disclosed. These valuation and revenue metrics indicate that the company operates on a small-cap scale, suggesting it is in a phase of significant expansion or market penetration rather than established maturity, which is consistent with its high revenue growth rate.
Financial Health
The company reported trailing twelve-month revenue of $10.02M alongside a net income of $-90,085,000 and an EBITDA of $-82,369,000. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure characterized by significant operating expenses that exceed gross profits, a common challenge for medical technology firms investing heavily in R&D and commercialization. Nyxoah SA reports N/A for free cash flow, which implies that the company's liquidity management is currently driven by cash reserves rather than operational cash generation. The firm holds $48.00M in cash against $42.08M in debt, resulting in a debt-to-equity ratio of 85.64, which suggests a leveraged balance sheet where debt obligations are substantial relative to shareholder equity. Despite the high leverage, the current ratio stands at 1.25, indicating that the company maintains sufficient current assets to cover its short-term liabilities. The return on equity is -111.0% and the return on assets is -37.7%, metrics that reveal management is currently utilizing shareholder capital and assets to generate negative returns, likely due to the high cash burn associated with the company's growth strategy. The gross margin is 63.1%, while the operating margin is -330.1% and the profit margin is 0.0%, highlighting that while the core product is priced well, overall operational efficiency has not yet translated into profitability.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, whereas the forward P/E is -2.09, a valuation metric that reflects the market's expectation of negative earnings persisting in the near term or a reliance on future profitability to justify current stock prices. The price-to-book ratio is 2.43, indicating that the market values the company at a premium of 143% over its book value, likely driven by the intangible value of its intellectual property and the potential of its pipeline. The price-to-sales ratio stands at 13.81 and the EV/EBITDA is -1.61, alternative metrics that suggest the market is pricing in significant future growth potential despite the current lack of earnings, as traditional earnings-based multiples are not applicable. The stock's 52-week high is $11.87 and the 52-week low is $3.02, placing the current valuation context within a wide trading range that reflects high volatility and investor sentiment shifts regarding the company's clinical and commercial milestones. The beta value is 0.62, which indicates that the stock's price volatility is historically lower than the broader market, though this metric can fluctuate significantly during periods of earnings uncertainty or regulatory news.
Growth & Income
Nyxoah SA reported a revenue growth rate of 346.9% year-over-year, while the earnings growth rate is N/A due to the company's ongoing losses. The disparity between the explosive revenue growth and the absence of positive earnings growth implies that the company is prioritizing top-line expansion and market capture over immediate profitability, a typical trajectory for early-stage medical device companies. As the company does not pay a dividend, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings and cash reserves to reinvest into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is essential for sustaining the 346.9% revenue growth, as the company relies on capital allocation to advance its Genio system and expand its commercial footprint in the obstructive sleep apnea treatment market.